Cadila Pharmaceuticals organised IAMICON 2014 (Indravadan Ambalal Modi Innovation Conclave), to highlight the innovation and excellence in the pharmaceuticals and Life Sciences sector.

Covering 50 cities across India, the event focussed on advances in the treatment of Tuberculosis and Cardiovascular diseases. Cadila is also committed to Government of India’s ‘TB-Mission 2020’, which seeks to eliminate Tuberculosis from the country. The platform brought together experts from the medical field.  Among the speakers were Professor Brendan Madden, Director, Endobronchial Intervention and Pulmonary Hypertension Services (UK); Kenneth J Giacin, chairman, StemCyte Inc. (USA); Dr Wise Young, chief science & medical advisor, StemCyte Inc. (USA); Professor Sir Anthony Coates, founder, Helperby Therapeutics Ltd (UK); and Dr. Nikhil Parchure, Consultant Cardiologist (UK)

“India’s pharmaceuticals sector has creditable contribution in providing affordable medicines to patients in India and across the globe. There have been bright sparks of innovation in our country, which have not received due attention. By showcasing such efforts every year and promoting the spirit of Indian innovation, IAMICON seeks to pay eternal tribute to Founder-Chairman Indravadan Ambalal Modi, the legendary Medicine Man of India, said Dr. Rajiv Modi, chairman and managing director, Cadila Pharmaceuticals Ltd.

Launched on November 14 at New Delhi, IAMICON 2014 held across the country on November 14-15-16 and November 21-22-23 in 50 cities across India. More than 300 national and international speakers and 20,000-plus doctors participated in India’s biggest medical knowledge conclave.

Amongst the leading R&D companies in India, Cadila launched the  first-in-the-world innovative products such as Polycap (5-in-1 polypill for prevention and treatment of Cardiovascular Diseases  and Risorine to treat Tuberculosis. In 2013, it introduced Mycidac-C the world’s first active immunotherapy for lung cancer at almost one-tenth the cost of those made by multinational companies.

“Besides the latest updates in medical science, IAMICON 2014 also spotlight the work of some eminent practitioners who have focussed on advancements in treating TB and Cardiovascular Diseases. Through the ‘Indravadan Ambalal Modi Academic Excellence Awards’, IAMICON also felicitated doctors with excellent academic performance in their post-graduate medical studies.